微波消融与腹腔镜肝叶切除术治疗肝血管瘤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2024.01.030

摘要/Abstract

摘要： 目的比较微波消融(MWA)与腹腔镜肝叶切除术(LH)治疗肝血管瘤(HH)患者的疗效。方法 2018年1月～2022年3月我院收治的94例HH患者,其中46例接受MWA治疗,48例接受LH治疗,术后随访1年。采用ELISA法检测血清肿瘤坏死因子-α(TNF-α)和白介素-6(IL-6)水平。结果 MWA组术中出血量、血流阻断时间、手术时间和术后住院日为(17.2±3.5)mL、(22.8±4.4)min、(158.0±31.8)min和(6.3±1.9)d,均显著少于或短于LH组【分别为(208.4±39.7)mL、(26.3±5.1)min、(228.5±43.2)min和(8.1±2.4)d,P<0.05】;手术前后,两组肝功能指标变化无统计学差异(P>0.05);在术后5 d,MWA组血清TNF-α和IL-6水平分别为(51.3±7.5)pg/ml和(18.3±3.5)pg/ml,均显著低于LH组【分别为(65.9±10.4)pg/ml和(26.8±4.9)pg/ml,P<0.05】;术后,MWA和LH治疗组感染或胆漏等并发症发生率分别为4.4%和8.3%,无显著性差异(P>0.05);术后随访1年发现,LH组无肝内血管瘤复发,MWA组43例(93.5%)病灶缩小幅度超过75%。结论采取MWA或LH治疗HH患者均能获得良好的疗效,但考虑到手术风险,在条件允许时应尽可能地采取MWA手术治疗。

关键词: 肝血管瘤, 微波消融, 腹腔镜肝叶切除术, 治疗

Abstract: Objective The purpose of this study was to compare the efficacy of microwave ablation (MWA) and laparoscopic hepatectomy (LH) in the treatment of patients with hepatic hemangiomas (HH). Methods 94 patients with HH were admitted to our hospital between January 2018 and March 2022, and were divided into two groups, receiving MWA in 46 cases and LH in 48 cases. All patients were followed-up for 1 year after operation. Serum tumor necrosis factor -α (TNF-α) and interleukin-6 (IL-6) levels were determined by ELISA. Results The intraoperative blood loss, blood flow blocking time, operation time and hospital stay in MWA-treated patients were (17.2±3.5)mL, (22.8±4.4)min, (158.0±31.8)min and (6.3±1.9)d, all significantly less or shorter than [(208.4±39.7) mL, (26.3±5.1)min, (228.5±43.2)min and (8.1±2.4)d, respectively, P<0.05] in patients receiving LH treatment; there were no significant differences as respect to liver function tests between the two groups before and after operation (P>0.05); five days after operation, serum TNF-α and IL-6 levels in patients with MWA treatment were (51.3±7.5)pg/ml and (18.3±3.5)pg/ml, both significantly lower than [(65.9±10.4)pg/ml and (26.8±4.9)pg/ml, respectively, P<0.05] in LH-treated patients; the incidences of post-operational complications, such as infections and bile leakage, in MWA- and LH-treated patients were 4.4% and 8.3% (P>0.05); at the end of one-year follow-up, no intrahepatic tumors relapsed in LH-treated patients, and the tumors shrank to 25% in 43 cases (93.5%) in MWA-treated patients. Conclusion The patients with HH could be managed by both MWA or LH, but we recommend the former because of the less body inflammatory reactions and rapid recovery.

Key words: Hepatic hemangiomas, Microwave ablation, Laparoscopy hepatectomy, Treatment

陶国清, 许其威, 李海锋. 微波消融与腹腔镜肝叶切除术治疗肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 117-120.

Tao Guoqing, Xu Qiwei, Li Haifeng. Comparison of microwave ablation and laparoscopic hepatectomy in the treatment of patients with hepatic hemangiomas[J]. Journal of Practical Hepatology, 2024, 27(1): 117-120.

参考文献

[1] 周正,刘玮.肝血管瘤、肝细胞癌和肝血管平滑肌脂肪瘤超声造影特点观察.实用肝脏病杂志,2021,24(6):911-914.
[2] Zavras N, Dimopoulou A, Machairas N,et al. Infantile hepatic hemangioma: current state of the art, controversies, and perspectives. Eur J Pediatr, 2020, 179(1):1-8.
[3] Aziz H, Brown ZJ, Baghdadi A,et al. A comprehensive review of hepatic hemangioma management. J Gastrointest Surg, 2022, 26(9):1998-2007.
[4] 高维克,戴朝六,许永庆,等.肝血管瘤患者手术治疗后生存质量评价.中华消化外科杂志,2019,18(12):1129-1135.
[5] 胡伟,张功铭,陈蒙,等.Laennec入路在腹腔镜解剖性右半肝叶切除术中的应用价值.中华消化外科杂志,2021,20(7):815-821.
[6] Izzo F, Granata V, Grassi R,et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist, 2019, 24(10):e990-e1005.
[7] 中华医学会.临床诊疗指南:消化系统疾病分册.北京:人民卫生出版社,2005:1-149.
[8] Li L, Xu L, Wang P,et al. Advantages of laparoscopic hepatic hemangioma surgery in quality of life: a prospective study. Surg Endosc, 2022, 36(12):8967-8974.
[9] Xiu W, Liu J, Li T,et al. Application value of computer-assisted surgery system in pediatric hepatic hemangioma. Pediatr Surg Int, 2021, 37(11):1575-1583.
[10] Gregory JJ, Patel KJ, Lancaster WP. Surgical resection of hepatic epithelioid hemangioendothelioma. Am Surg, 2019, 85(7):e361-e362.
[11] Wang S, Gao R, Zhao S, et al. Safety and effectiveness of laparoscopic intratumoral resection facilitated by coagulation of giant hepatic hemangioma: a matched case-control study and literature review. Surg Endosc, 2022, 36(7):5149-5159.
[12] 汪建初,姚天尉,罗宗将,等.无血流阻断的腹腔镜肝右后叶血管瘤切除28例临床分析.中华肝胆外科杂志,2019,25(6):415-417.
[13] 徐奇奇,朱卫华,甘丽云,等.MWA与手术切除治疗小肝癌的综合疗效比较.中华普通外科杂志,2021,36(9):649-652.
[14] Zhang HL, Meng HB, Li XL,et al. Laparoscopy-guided percutaneous microwave ablation for symptomatic 12.8 cm hepatic hemangioma with low blood loss and short hospital stay post-operation: a case report and literature review. Clin Hemorheol Microcirc, 2021, 77(2):165-171.
[15] Kong J, Gao R, Wu S,et al. Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching. Eur Radiol, 2022, 32(5):3309-3318.
[16] Wang LZ, Wang KP, Mo JG,et al. Minimally invasive treatment of hepatic hemangioma by transcatheter arterial embolization combined with microwave ablation: a case report. World J Clin Cases, 2021, 9(24):7154-7162.
[17] 郝晓沛,代坤甫,马帅,等.腹腔镜肝切除手术与同期开腹手术治疗肝脏恶性肿瘤的单中心回顾性研究.中华普通外科杂志,2019,34(2):132-135.
[18] Yan C, Li BH, Sun XT,et al. Laparoscopic hepatectomy is superior to open procedures for hepatic hemangioma. Hepatobiliary Pancreat Dis Int, 2021, 20(2):142-146.
[19] Mei M, Shi H, Cheng Y,et al. Risk factors for hypercoagulability after laparoscopic hepatic haemangioma resection. J Minim Access Surg, 2023, 19(2):245-251.
[20] Shi Y, Song J, Ding M,et al. Microwave ablation versus transcatheter arterial embolization for large hepatic hemangiomas: clinical outcomes. Int J Hyperthermia, 2020, 37(1):938-943.
[21] Tang X, Ding M, Lu B,et al. Outcomes of ultrasound-guided percutaneous microwave ablation versus surgical resection for symptomatic large hepatic hemangiomas. Int J Hyperthermia, 2019, 36(1):632-639.
[22] 陈云,周松,李鑫,等.三维可视化手术规划系统在肝脏大血管瘤MWA治疗中的价值.中华肝胆外科杂志,2019,25(12):890-893.
[23] Leuchte K, Staib E, Thelen M,et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother, 2021, 70(4):893-907.
[24] Yan Z, Khorasani R, Levesque VM,et al. Liver tumor F-18 FDG-PET before and immediately after microwave ablation enables imaging and quantification of tumor tissue contraction. Eur J Nucl Med Mol Imaging, 2021, 48(5):1618-1625.

微波消融与腹腔镜肝叶切除术治疗肝血管瘤患者疗效研究^*

Comparison of microwave ablation and laparoscopic hepatectomy in the treatment of patients with hepatic hemangiomas

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈从新, 陈曦, 王莉苹, 赵秋香, 刘颖, 周海洋. 糖皮质激素在肝病治疗中的应用[J]. 实用肝脏病杂志, 2024, 27(3): 321-323.
[2]	赵玉雯, 朱传龙. 肝硬化营养不良及肌少症治疗研究进展[J]. 实用肝脏病杂志, 2024, 27(3): 324-328.
[3]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[4]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[5]	程艳洁, 王鹏飞, 李峻. 水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 349-352.
[6]	徐秋萍, 黄彬, 陈敏, 余静. 泼尼松与泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者外周血MDSCs百分比、肝组织白细胞介素-35和血清CD38水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 374-377.
[7]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[8]	李菊兰, 张华堂, 郑怡娟, 余雪平, 邓勇, 苏智军. 恩替卡韦联合扶正化瘀片治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 402-405.
[9]	蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东. 基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(3): 406-409.
[10]	闫振, 赵博文, 林国英, 殷和良. 影像学三维可视化技术指导肝切除术治疗肝细胞癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 438-441.
[11]	李玮健, 刘昕, 舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 450-453.
[12]	王苓入, 苏虹, 郝晓炜, 李娜. 超声引导下PTGD联合聚桂醇硬化治疗单纯性肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 454-457.
[13]	徐旭, 施漪雯, 范建高. 肝豆状核变性治疗现状与展望^*[J]. 实用肝脏病杂志, 2024, 27(3): 477-480.
[14]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[15]	李兴泉, 杨春, 李诗源, 翁凯, 彭麟. 奥比帕利联合达塞布韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 177-180.